Buyback and Cancellation of Deferred Shares

RNS Number : 6638S

IXICO plc

23 December 2016

 

23 December 2016

IXICO plc

("IXICO" or the "Company")

Buyback and cancellation of Deferred Shares

IXICO, the brain health company, announces that it has today repurchased, for nominal value, and cancelled deferred shares of 49 pence each in the share capital of the Company. The deferred shares

were issued as part of a share capital restructuring undertaken in conjunction with the acquisition of Optimal Medicine Group and as announced on 18 November 2015.

For further information please contact:

IXICO plc Derek Hill, Chief Executive Officer Susan Lowther, Chief Financial Officer	Tel: [phone]
Shore Capital (Nomad and Broker) Bidhi Bhoma / Edward Mansfield	Tel: [phone]
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan/Matthew Moss	Tel: [phone]

About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions.  In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes.  In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com

 

END

 

 

MSCAKBDKOBDDBBB